Posted on 1/13/20
IDEAYA Biosciences and Boston Children's Hospital Collaborate
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced that the company has entered into a . . .
Posted on 1/9/20
Oramed Pharmaceuticals Issues Letter to Shareholders
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the . . .
Posted on 1/9/20
Omnicom Public Relations Group Forms Strategic Alliance with LaVoieHealthScience
Omnicom Public Relations Group (OPRG), a division of Omnicom Group (NYSE: OMC) announced today a strategic alliance with LaVoieHealthScience (LHS) to bring global clients a broader . . .
Posted on 1/9/20
Sebacia Announces Leadership Update and Acquisition of Silver Photoparticle Technology Assets from Sienna Biopharmaceuticals
Sebacia, Inc., a privately held commercial stage dermatology and aesthetics company, today provided a business update, first announcing an update to its leadership team. Mr. Chuck . . .
Posted on 1/9/20
Merck's Blockbuster Drug Wins Key New FDA Approval
One of the world's most successful drugs, Merck's (NYSE:MRK) Keytruda, stands to become even more prominent following an important new approval. The U.S. Food and Drug . . .
Posted on 1/9/20
EHE Health Partners with Cedar Gate Technologies
EHE Health (EHE), the pioneer and nation's largest provider of preventive health care services, announced its strategic partnership with Cedar Gate Technologies (Cedar Gate). EHE provides . . .
Posted on 1/8/20
Prisma Health Renews Partnership With Prudential
NEWARK, N.J.--(BUSINESS WIRE)--Prudential Retirement will continue its decade-long relationship with Prisma Health, South Carolina’s largest not-for-profit health organization serving more than 1.2 million patients annually, as . . .
Posted on 1/8/20
Merck's Keytruda Misses an Important Lung Cancer Goal
Merck's cancer immunotherapy finally hit a stumbling block in a pivotal study with lung cancer patients that caused the stock to slip 1.5% on Tuesday morning. . . .
Posted on 1/7/20
Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration
NEW YORK & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (Nasdaq: TYME), an emerging biotechnology company developing cancer metabolism-based therapies, and Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX), today . . .
Posted on 1/7/20
Bristol-Myers Squibb Completes Divestment of Manufacturing Facility in Anagni, Italy
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufacturing and . . .
Posted on 1/7/20
Bioasis Announces Shares for Debt Transaction
GUILFORD, Conn.--(BUSINESS WIRE)--BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the . . .
Posted on 1/6/20
OWYN Announces Growth Investment Led by PowerPlant Ventures
OWYN (Only What You Need), a leading brand in plant-based protein beverages and other functional nutrition products, today announced a growth investment round led by PowerPlant . . .
Posted on 1/6/20
Slayback Pharma Announces Investment of $50M by The Everstone Group
Slayback Pharma LLC today announced an agreement with The Everstone Group to invest up to US$50 million in Series B funding.
Posted on 1/6/20
Merck Establishes Strategic Oncology Collaboration with Taiho and Astex
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced an exclusive worldwide research collaboration and license agreement with Taiho . . .
Posted on 1/6/20
Johnson & Johnson: The Pharma Giant That Continues To Grow
SummaryStock trades near the all-time highs.Company is facing legal headwinds in US.It reported better-than-expected earnings in Q3.Looking for a helping hand in the market? Members of . . .
Posted on 1/6/20
Is Johnson & Johnson Stock a Buy?
Johnson & Johnson (NYSE:JNJ) didn't have a great year in 2019. Sure, the stock was up 13%. However, that wasn't even half the gain that the . . .
Posted on 1/6/20
Is Cigna's Stock a Buy?
Healthcare provider Cigna (NYSE:CI) was having a lackluster 2019 until the past three months; since then, its stock has been soaring more than 35%, soundly outperforming . . .
Posted on 1/6/20
Here's Why Bristol-Myers Squibb Jumped 12.7% in December
What happenedShares of Bristol-Myers Squibb (NYSE:BMY) gained nearly 13% last month, according to data from S&P Global Market Intelligence. The trek higher capped off a solid . . .
Posted on 1/6/20
AzurRx BioPharma Appoints Daniel Schneiderman as CFO
NEW YORK, Jan. 03, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, . . .
Posted on 1/3/20
Johnson & Johnson: Litigation Risk Discounting Shares Relative To Market
SummaryShares of Johnson & Johnson have underperformed, largely because of bad publicity regarding various lawsuits that the company has been fighting.The financial strength of Johnson & . . .
Posted on 1/3/20
Better Buy: Abbott Laboratories vs. Pfizer
Investors looking for large-cap, dividend-paying healthcare stocks have plenty of options. Whether it's large-scale drug manufacturers or medical technology providers, there's enough choice to suit whatever . . .
Posted on 1/3/20
Cigna: The Health Services Powerhouse (Part 2)
Summary The HMO industry has consolidated in recent years. Cigna has enjoyed annual revenue growth of 11% and compound annual earnings per share growth of 15% . . .
Posted on 1/2/20
If You Invested $10,000 in Johnson & Johnson's IPO, This Is How Much Money You'd Have Now
On Sept. 24, 1944, Johnson & Johnson (NYSE:JNJ) went public at $37.50 a share, after 58 years of operating privately. Johnson & Johnson was founded by . . .
Posted on 1/2/20
Pfizer Just Raised Its Dividend: Is Now a Good Time to Buy?
2019 wasn't a great year for Pfizer (NYSE:PFE). The company's shares decreased by 10% during the year, whereas the performance of the pharmaceuticals industry -- as . . .
Posted on 1/2/20
Does Johnson & Johnson’s Dividend Make It A Buy?
Finding a good dividend stock can be a challenge, as investors need to consider more than just the size of a stock's payouts. The company's stability, . . .
New York
